Literature DB >> 23731707

Do community-level predictors of pneumococcal carriage continue to play a role in the conjugate vaccine era?

K K Hsu1, S L Rifas-Shiman2, K M Shea3, K P Kleinman2, G M Lee2, M Lakoma2, S I Pelton1, J A Finkelstein2, S S Huang4.   

Abstract

This paper examined whether previously identified community-level factors (high proportion of crowded households and/or persons below the poverty level) remained associated with childhood pneumococcal carriage in the heptavalent pneumococcal conjugate vaccine (PCV7) era. Using logistic regression, individual factors were used to develop base models to which community-level factors were added to evaluate impact on pneumococcal carriage within two paediatric study cohorts from Massachusetts (urban Boston, outside Boston). Six years after introduction of universal childhood PCV7 vaccination, we found no consistent evidence that census tract characteristics (e.g. population size and density, age and race distribution, percent participating in group childcare, parental education, percent lacking in-unit plumbing, poverty, and community stability) affected odds of pneumococcal carriage when added to individual predictors (e.g. younger age, current respiratory tract infections, and attendance in group childcare). How community-level factors influence pneumococcal carriage continues to change in the era of increasing immunization coverage.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23731707      PMCID: PMC3849242          DOI: 10.1017/S0950268813000794

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   2.451


  12 in total

1.  Continued impact of pneumococcal conjugate vaccine on carriage in young children.

Authors:  Susan S Huang; Virginia L Hinrichsen; Abbie E Stevenson; Sheryl L Rifas-Shiman; Ken Kleinman; Stephen I Pelton; Marc Lipsitch; William P Hanage; Grace M Lee; Jonathan A Finkelstein
Journal:  Pediatrics       Date:  2009-07       Impact factor: 7.124

2.  Post-PCV7 changes in colonizing pneumococcal serotypes in 16 Massachusetts communities, 2001 and 2004.

Authors:  Susan S Huang; Richard Platt; Sheryl L Rifas-Shiman; Stephen I Pelton; Donald Goldmann; Jonathan A Finkelstein
Journal:  Pediatrics       Date:  2005-09       Impact factor: 7.124

3.  Licensure of a 13-valent pneumococcal conjugate vaccine (PCV13) and recommendations for use among children - Advisory Committee on Immunization Practices (ACIP), 2010.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2010-03-12       Impact factor: 17.586

4.  Use of antibiotics and risk factors for carriage of Streptococcus pneumoniae: a longitudinal household study in the United Kingdom.

Authors:  R G Pebody; O Morgan; Y Choi; R George; M Hussain; N Andrews
Journal:  Epidemiol Infect       Date:  2008-07-31       Impact factor: 2.451

5.  Immunization with the 7-valent conjugate pneumococcal vaccine: impact evaluation, continuing surveillance and future perspectives.

Authors:  Angela Bechini; Sara Boccalini; Paolo Bonanni
Journal:  Vaccine       Date:  2009-02-05       Impact factor: 3.641

6.  Changing serotypes causing childhood invasive pneumococcal disease: Massachusetts, 2001-2007.

Authors:  Katherine K Hsu; Kimberly M Shea; Abbie E Stevenson; Stephen I Pelton
Journal:  Pediatr Infect Dis J       Date:  2010-04       Impact factor: 2.129

7.  Impact of a 16-community trial to promote judicious antibiotic use in Massachusetts.

Authors:  Jonathan A Finkelstein; Susan S Huang; Ken Kleinman; Sheryl L Rifas-Shiman; Christopher J Stille; James Daniel; Nancy Schiff; Ron Steingard; Stephen B Soumerai; Dennis Ross-Degnan; Donald Goldmann; Richard Platt
Journal:  Pediatrics       Date:  2008-01       Impact factor: 7.124

8.  Epidemiologic studies of Streptococcus pneumoniae in infants: acquisition, carriage, and infection during the first 24 months of life.

Authors:  B M Gray; G M Converse; H C Dillon
Journal:  J Infect Dis       Date:  1980-12       Impact factor: 5.226

9.  Community-level predictors of pneumococcal carriage and resistance in young children.

Authors:  Susan S Huang; Jonathan A Finkelstein; Sheryl L Rifas-Shiman; Ken Kleinman; Richard Platt
Journal:  Am J Epidemiol       Date:  2004-04-01       Impact factor: 4.897

10.  Antibiotic-resistant Streptococcus pneumoniae in the heptavalent pneumococcal conjugate vaccine era: predictors of carriage in a multicommunity sample.

Authors:  Jonathan A Finkelstein; Susan S Huang; James Daniel; Sheryl L Rifas-Shiman; Ken Kleinman; Donald Goldmann; Stephen I Pelton; Alfred DeMaria; Richard Platt
Journal:  Pediatrics       Date:  2003-10       Impact factor: 7.124

View more
  4 in total

1.  Nasopharyngeal carriage of Streptococcus pneumoniae among children in an urban setting in Brazil prior to PCV10 introduction.

Authors:  Ana Paula de O Menezes; Jailton Azevedo; Mariela C Leite; Leila C Campos; Marcelo Cunha; Maria da Gloria S Carvalho; Mitermayer G Reis; Albert I Ko; Daniel M Weinberger; Guilherme Ribeiro; Joice N Reis
Journal:  Vaccine       Date:  2015-12-29       Impact factor: 3.641

2.  Immunization, Antibiotic Use, and Pneumococcal Colonization Over a 15-Year Period.

Authors:  Grace M Lee; Ken Kleinman; Stephen Pelton; Marc Lipsitch; Susan S Huang; Matt Lakoma; Maya Dutta-Linn; Melisa Rett; William P Hanage; Jonathan A Finkelstein
Journal:  Pediatrics       Date:  2017-10-04       Impact factor: 7.124

3.  Pneumococcal Colonization in the Familial Context and Implications for Anti-Pneumococcal Immunization in Adults: Results from the BINOCOLO Project in Sicily.

Authors:  Fabio Tramuto; Emanuele Amodio; Giuseppe Calamusa; Vincenzo Restivo; Claudio Costantino; Francesco Vitale
Journal:  Int J Mol Sci       Date:  2017-01-06       Impact factor: 5.923

4.  Dynamics and Determinants of Pneumococcal Antibodies Specific against 13 Vaccine Serotypes in the Pre-Vaccination Era.

Authors:  Annemarijn C Prins-van Ginkel; Guy A M Berbers; Lucienne H Grundeken; Irina Tcherniaeva; Jelle I Wittenberns; Karin Elberse; Liesbeth Mollema; Hester E de Melker; Mirjam J Knol
Journal:  PLoS One       Date:  2016-01-21       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.